Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1619-7089
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy? ; day:3 ; month:1 ; year:2019 ; pages:1-11
European journal of nuclear medicine and molecular imaging ; (3.1.2019), 1-11
- Creator
-
Santos, José Carlos dos
Schäfer, Martin
Bauder-Wüst, Ulrike
Lehnert, Wencke
Leotta, Karin
Morgenstern, Alfred
Kopka, Klaus
Haberkorn, Uwe
Mier, Walter
Kratochwil, Clemens
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00259-018-4220-z
- URN
-
urn:nbn:de:101:1-2019020819270481338124
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:03 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Santos, José Carlos dos
- Schäfer, Martin
- Bauder-Wüst, Ulrike
- Lehnert, Wencke
- Leotta, Karin
- Morgenstern, Alfred
- Kopka, Klaus
- Haberkorn, Uwe
- Mier, Walter
- Kratochwil, Clemens
- SpringerLink (Online service)
Other Objects (12)
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3
Structural modifications of PSMA ligands to optimize their pharmacokinetics
PSMA ligands for diagnosis and therapy of prostate cancer
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients
Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617
Image-based dosimetry for 225Ac-PSMA-I&T therapy using quantitative SPECT
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3
Structural modifications of PSMA ligands to optimize their pharmacokinetics
PSMA ligands for diagnosis and therapy of prostate cancer
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients
Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617
Image-based dosimetry for 225Ac-PSMA-I&T therapy using quantitative SPECT
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3
Structural modifications of PSMA ligands to optimize their pharmacokinetics
PSMA ligands for diagnosis and therapy of prostate cancer
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients
Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617